These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported Terminated 2004-002821-30 Study of the efficacy of intravesical instillations of interleukin-2 in treatment of superficial bladder cancer 2009-04-16 due-trials
Ongoing 2004-003906-81 Chemoradiation with once weekly gemcitabine for invasive bladder cancer not-yet-due
Not reported 2007-001818-16 Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients with High Risk Chronic B Lymphocytic Leukemia 2011-12-16 due-trials
Reported results 2008-006309-17 Significance of prognostic and predictive factors for the efficacy and safety of neoadjuvant chemotherapy in combination with chemoradiation administered in patients with locally advanced cervical can... 2013-10-01 due-trials
Not reported 2010-023205-35 Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients with Chronic B Lymphocytic Leukemia 2016-01-06 due-trials
Not reported Terminated 2011-000908-18 Treatment Protocol for young adults (18-45 years of age) with Acute Lymphoblastic Leukemia 2016-04-21 due-trials
Ongoing 2019-000661-20 Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open label clinical trial. Ivabradino įtaka kardiotoksinės chemoterapijos indukuotos ankstyvosios miokardo pažai... not-yet-due
Ongoing 2020-001366-11 An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care not-yet-due
Ongoing 2020-005128-12 An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study not-yet-due
Ongoing 2020-005214-18 An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia − An open-label randomized controlled study not-yet-due